Patent · US Expired

Natural or synthetic retroelement sequence enabling nucleotide sequence insertion into a eukaryotic cell

US6200800A · kind A · utility

15Cited by
1References
22Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 11, 1998
Grant dateMar 13, 2001
Priority date
Expiry dateMay 11, 2018

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2800/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Retroviral vectors contain cis-acting viral elements for the expression, encapsidation, reverse transcription and integration of the retroviral genome nucleic acid sequence. However, these elements are not useful in the integrated provirus and may cause many problems. A retroviral vector is provided for eliminating most of the viral elements. This vector uses, among other things, the bacteriophage P1 Cre-lox recombination system. The 32-nucleotide loxP site is inserted into 3'LTR sequence U3 with the gene to be inserted into the cell. After loxP duplication using the LTR, the LTRs may be recombined by enzyme Cre. The structure of the resulting provirus in the host genome corresponds to a single LTR carrying a single copy of the gene to be inserted into the cell. If the Cre expression unit is inserted between the two LTRS, only single-LTR proviral structures are found following infection with the retroviral vector.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.